logo-loader
viewAIM ImmunoTech Inc.

Hemispherx treats first patient with cancer drug Ampligen in Phase 2 clinical trials

The study looks at the effectiveness of ampligen in combination with the drug pembrolizumab at treating ovarian cancer

cancer cells
Hemispherx believes that Ampligen could have anti-viral and anti-cancer properties

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) took a key step forward in its Phase 2 clinical trial on Wednesday after it announced that the first patient has been treated with its flagship drug Ampligen.

The study looks at the effectiveness of ampligen in combination with the drug pembrolizumab at treating ovarian cancer. It is being run out of the University of Pittsburgh Medical Center.

Shares of Hemispherx jumped 21.8% on Wednesday afternoon in New York.

READ: Hemispherx Biopharma’s well-funded to take promising cancer drug Ampligen through clinical trials

Florida-based Hemispherx believes that Ampligen could have anti-viral and anti-cancer properties. Prior clinical trials of the drug looked at patients with renal cell carcinoma and malignant melanoma.

The Phase 1 initial study indicated that Ampligen is generally well-tolerated when administrated through the abdominal cavity.

The Phase 2 clinical trials are being run under the leadership of principal investigator Dr. Robert Edwards and is expected to treat 45 patients.

Clinically significant

 “Ampligen has the potential to be clinically significant because a robust killer T-cell population in the tumor microenvironment without attracting Treg cells is important to help optimize checkpoint blockade induced tumor shrinkage," said Dr. Edwards in a statement.

Ovarian cancer is expected to be the cause of death for 152,000 people this year, according to Hemispherx.

“With this new large-scale study funded by an industry grant, Hemispherx and the team at Magee-Women's Hospital of the University of Pittsburgh School of Medicine are focused on developing a potentially life-saving therapy to meet this critical and unmet medical need," said CEO Thomas K. Equels.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: AIM ImmunoTech Inc.

Price: 0.4903 USD

NYSE:AIM
Market: NYSE
Market Cap: $2.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc. named herein, including the promotion by the Company of AIM ImmunoTech Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Hemispherx Biopharma releases 'well tolerated' data for...

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Thomas Equels tells Protactive that a final report on its phase 1 trial supporting the safety of using its flagship drug Ampligen as a combination therapy to treat recurrent ovarian cancer found that it was “well tolerated." Equels explains the...

on 08/19/2019

2 min read